{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-011202","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2022-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.113165+00:00","generated_at":"2026-06-24T00:20:09.148910+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Edesa Biotech Q3 net loss $5.79M ($0.37/sh); Phase 3 ARDS study expanded; Phase 2b on track","bullets":["Net loss for Q3 fiscal 2022: $5.79M ($0.37/sh) vs $4.76M ($0.36/sh) in prior year; nine-month loss $14.74M ($1.04/sh).","Phase 3 ARDS study for Covid-19 expanded to second cohort; parallel recruitment underway.","Phase 2b ACD study expects to randomize all 210 subjects by Q4 2022 with topline data in early 2023.","Cash and equivalents $12.81M; working capital $9.52M at June 30, 2022.","Operating expenses for Q3 were $5.80M, down from $6.07M YoY, driven by lower G&A and share-based compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-011202","json":"https://secwatch.observer/filing/0001654954-22-011202.json","markdown":"https://secwatch.observer/filing/0001654954-22-011202.md","text":"https://secwatch.observer/filing/0001654954-22-011202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495422011202/0001654954-22-011202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495422011202/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:20:09.148910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}